Scientists at the University of Oxford are racing to create the first vaccine for the Bundibugyo strain of Ebola, responding to a serious outbreak in the Democratic Republic of the Congo that has led to approximately 750 suspected cases and 177 deaths. The World Health Organization (WHO) has escalated the outbreak's risk level from 'high' to 'very high', although the international risk remains low. The Bundibugyo strain, which can cause severe hemorrhagic fever, has only been responsible for two prior outbreaks. The Oxford team is employing the ChAdOx1 vaccine platform, which was instrumental in the rapid development of the COVID-19 vaccine. This innovative approach involves using a harmless chimpanzee cold virus to deliver genetic material from the Bundibugyo virus, training the immune system to respond effectively without causing disease. If animal trials yield positive results, clinical trials could commence within two to three months. The Serum Institute of India will assist in mass production if the vaccine proves effective, highlighting the urgency of developing vaccines for emerging viruses in our interconnected world.